Raynaud's phenomenon (primary)
Abstract
Introduction: Raynaud's phenomenon is an episodic vasospasm of the peripheral arteries, causing pallor, followed by cyanosis and redness with pain, and sometimes paraesthesia. On rare occasions it can lead to ulceration of the fingers and toes (and in some cases of the ears or nose). This review focuses on primary (idiopathic) Raynaud's phenomenon, occurring in the absence of an underlying disease. The prevalence of primary Raynaud's phenomenon varies by sex, country, and exposure to workplace vibration.
Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments for primary Raynaud's phenomenon? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Results: We found 16 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: amlodipine, diltiazem, exercise, inositol nicotinate, keeping warm, moxisylyte (thymoxamine), naftidrofuryl oxalate, nicardipine, nifedipine, prazosin, and smoking cessation.
Similar articles
-
Raynaud's phenomenon (primary).BMJ Clin Evid. 2008 Dec 16;2008:1119. BMJ Clin Evid. 2008. PMID: 19445785 Free PMC article.
-
Raynaud's phenomenon (primary).BMJ Clin Evid. 2013 Oct 10;2013:1119. BMJ Clin Evid. 2013. PMID: 24112969 Free PMC article.
-
Raynaud's phenomenon (secondary).BMJ Clin Evid. 2008 Sep 26;2008:1125. BMJ Clin Evid. 2008. PMID: 19445801 Free PMC article.
-
Raynaud's phenomenon (secondary).BMJ Clin Evid. 2014 Oct 14;2014:1125. BMJ Clin Evid. 2014. PMID: 25322727 Free PMC article.
-
Calcium channel blockers for primary and secondary Raynaud's phenomenon.Cochrane Database Syst Rev. 2017 Dec 13;12(12):CD000467. doi: 10.1002/14651858.CD000467.pub2. Cochrane Database Syst Rev. 2017. PMID: 29237099 Free PMC article.
Cited by
-
Vasodilators for primary Raynaud's phenomenon.Cochrane Database Syst Rev. 2021 May 17;5(5):CD006687. doi: 10.1002/14651858.CD006687.pub4. Cochrane Database Syst Rev. 2021. PMID: 33998674 Free PMC article.
-
Behaviour change interventions for the management of Raynaud's phenomenon: a systematic literature review.BMJ Open. 2018 Dec 14;8(12):e024528. doi: 10.1136/bmjopen-2018-024528. BMJ Open. 2018. PMID: 30552281 Free PMC article.
References
-
- Brand FN, Larson MG, Kannel WB, et al. The occurrence of Raynaud's phenomenon in a general population: the Framingham Study. Vasc Med 1997;2:296–301. - PubMed
-
- Rodriguez Garcia JL, Sabin Ruiz J. Raynaud's phenomenon. Rev Clin Esp 1989;184:311–321. [In Spanish] - PubMed
-
- Riera G, Vilardell M, Vaque J, et al. Prevalence of Raynaud's phenomenon in a healthy Spanish population. J Rheumatol 1993;20:66–69. - PubMed
-
- Inaba R, Maeda M, Fujita S, et al. Prevalence of Raynaud's phenomenon and specific clinical signs related to progressive systemic sclerosis in the general population of Japan. Int J Dermatol 1993;32:652–655. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous